Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Am J Surg. 2024 Oct;236:115794. doi: 10.1016/j.amjsurg.2024.115794. Epub 2024 Jun 5.
The role of immune-oncology (IO) therapy in soft tissue sarcoma (STS) is underexplored. This study characterized IO use in STS.
This is a retrospective analysis of patients with a soft tissue mass in the National Cancer Database, 2011-2021. Patients were categorized by IO receipt status. Groupwise testing and proportional trend tests were performed with Chi-squared tests. Multivariate logistic regression was performed to assess factors associated with IO receipt.
Of the 103,092 patients with STS, 1935 (1.9 %) received or were recommended IO therapy. IO use increased 10-fold (0.24 %-2.5 % from 2011 to 2021; p < 0.0001). Patients had higher odds of receiving IO when having higher grade tumors and metastatic disease, and when treated at an academic research center (all p < 0.001).
IO use in STS is low but increasing and primarily used in the metastatic setting. Future studies should identify biomarkers of IO response and facilitators for treatment receipt.
免疫肿瘤学（IO）疗法在软组织肉瘤（STS）中的作用尚未得到充分探索。本研究对 STS 中的 IO 使用情况进行了描述。
这是一项对 2011 年至 2021 年间国家癌症数据库中患有软组织肿块的患者进行的回顾性分析。患者根据 IO 接受情况进行分类。采用卡方检验进行组间检验和比例趋势检验。采用多变量逻辑回归评估与 IO 接受相关的因素。
在 103092 例 STS 患者中，有 1935 例（1.9%）接受或被推荐 IO 治疗。IO 的使用增加了 10 倍（2011 年至 2021 年期间从 0.24%增加到 2.5%；p<0.0001）。当患者的肿瘤分级较高、发生转移疾病以及在学术研究中心接受治疗时，他们更有可能接受 IO（均 p<0.001）。
STS 中 IO 的应用率较低，但呈上升趋势，主要用于转移性疾病。未来的研究应确定 IO 反应的生物标志物和治疗接受的促进因素。
